Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Merck’s Covid-19 push narrows further
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Molnupiravir’s big day draws near
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
